Locus Biosciences

Locus Biosciences

  • Founded: 2015
  • Location: Morrisville, NC
  • Employee range: 50 - 200
  • Clinical stage: Clin2/Clin3
  • Therapy area: E. coli UTI
  • Drug types: INF, GI
  • Lead product: LBP-EC01
  • Product link:
  • Funding: $35M B May 2022; $17M A Nov 2017
  • Investors: Artis Ventures, Tencent Holdings, Viking Global Investors, Johnson and Johnson Innovation – JJDC, Inc, Discovery Innovations

job board

Short description:

CRISP-engineered Bacteriophage Therapeutics

Drug notes:

LBP-PA01 Clin0 P. aeruginosa infections; LBP-SA01 Clin0 S. aureus infections; LBP-KA01 Clin0 K. pneumoniae infections; undisclosed RD IBD

Long description:

Locus Biosciences is using precision medicine technology to revolutionize the treatment of bacterial disease. The human microbiome includes the collection of microbes that live on or in the human body playing various important roles for health. When the balance is disrupted infections and diseases can arise. Locus is building precision medicines that target the microbiome and restore the balance. Their lead program, LBP-EC01, is a therapy designed to target E.coli infections. The cocktail therapy includes genetically engineered bacteriophages that can precisely remove E.coli in patients with urinary tract infections.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy